Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 46Multiple Myeloma 45Lymphoma 43Neoplasm Metastasis 40Breast Neoplasms 38Lung Neoplasms 37Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 30Leukemia, Myeloid, Acute 28Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 25Hematologic Neoplasms 22Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Lymphoma, Non-Hodgkin 20Glioma 20Carcinoma, Renal Cell 19Sarcoma 18Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Myelodysplastic Syndromes 15Burkitt Lymphoma 15Neuroblastoma 14Lymphoma, Large B-Cell, Diffuse 13Fallopian Tube Neoplasms 13Ependymoma 13Carcinoma 13Brain Neoplasms 13Thyroid Neoplasms 12

Interventions

cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Arthritis, Rheumatoid × 30 days × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡